This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fan, J. Articles by Maki, R. A. Search for Related Content PubMed PubMed Citation Articles by Fan, J. Articles by Maki, R. A.

A Point Mutation in the Human Melanin Concentrating Hormone Receptor 1 Reveals an Important Domain for Cellular Trafficking

Neurocrine Biosciences, Inc., San Diego, California 92113

Address all correspondence and requests for reprints to: Rich Maki, Neurocrine Biosciences, Inc., 12790 El Camino Real, San Diego, California 92113. E-mail: rmaki{at}neurocrine.com.

G protein-coupled receptors (GPCRs) are heptahelical integral membrane proteins that require cell surface expression to elicit their effects. The lack of appropriate expression of GPCRs may be the underlying cause of a number of inherited disorders. There is evidence that newly synthesized GPCRs must attain a specific conformation for their correct trafficking to the cell surface. In this study, we show that a single point mutation in human melanin-concentrating hormone receptor (hMCHR1) at position 255 (T²⁵⁵A), which is located at the junction of intracellular loop 3 and transmembrane domain 6, reduces the hMCHR1 cell surface expression level to 20% of that observed for the wild-type receptor. Most of these mutant receptors are located intracellularly, as opposed to the wild-type receptor, which is located primarily on the cell surface. Immunoprecipitation experiments show that hMCHR1-T²⁵⁵A has reduced glycosylation compared with the wild-type receptor and is associated with the chaperone protein, calnexin, and it colocalizes in the endoplasmic reticulum with KDEL-containing proteins. We also demonstrate that a cell-permeable small molecule antagonist of hMCHR1 can function as a pharmacological chaperone to restore cell surface expression of this and other MCHR1 mutants to wild-type levels. Once rescued, the T²⁵⁵A mutant couples to G_q proteins as efficiently as the wild-type receptor. These data suggest that this single mutation produces an hMCHR1 that folds incorrectly, resulting in its retention in the endoplasmic reticulum, but once rescued to the cell surface can still function normally.

This article has been cited by other articles:

				D. Yasuda, T. Okuno, T. Yokomizo, T. Hori, N. Hirota, T. Hashidate, M. Miyano, T. Shimizu, and M. Nakamura Helix 8 of leukotriene B4 type-2 receptor is required for the folding to pass the quality control in the endoplasmic reticulum FASEB J, May 1, 2009; 23(5): 1470 - 1481. [Abstract] [Full Text] [PDF]

				P. M. H. Markkanen and U. E. Petaja-Repo N-Glycan-mediated Quality Control in the Endoplasmic Reticulum Is Required for the Expression of Correctly Folded {delta}-Opioid Receptors at the Cell Surface J. Biol. Chem., October 24, 2008; 283(43): 29086 - 29098. [Abstract] [Full Text] [PDF]

				P. M. Conn, A. Ulloa-Aguirre, J. Ito, and J. A. Janovick G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo Pharmacol. Rev., September 1, 2007; 59(3): 225 - 250. [Abstract] [Full Text] [PDF]

				Z. Jin, I. Tietjen, L. Bu, L. Liu-Yesucevitz, S. K. Gaur, C. A. Walsh, and X. Piao Disease-associated mutations affect GPR56 protein trafficking and cell surface expression Hum. Mol. Genet., August 15, 2007; 16(16): 1972 - 1985. [Abstract] [Full Text] [PDF]

				T. T. Leskela, P. M. H. Markkanen, E. M. Pietila, J. T. Tuusa, and U. E. Petaja-Repo Opioid Receptor Pharmacological Chaperones Act by Binding and Stabilizing Newly Synthesized Receptors in the Endoplasmic Reticulum J. Biol. Chem., August 10, 2007; 282(32): 23171 - 23183. [Abstract] [Full Text] [PDF]

				S. R. Hawtin Pharmacological Chaperone Activity of SR49059 to Functionally Recover Misfolded Mutations of the Vasopressin V1a Receptor J. Biol. Chem., May 26, 2006; 281(21): 14604 - 14614. [Abstract] [Full Text] [PDF]

				J. Robert, C. Auzan, M. A. Ventura, and E. Clauser Mechanisms of Cell-surface Rerouting of an Endoplasmic Reticulum-retained Mutant of the Vasopressin V1b/V3 Receptor by a Pharmacological Chaperone J. Biol. Chem., December 23, 2005; 280(51): 42198 - 42206. [Abstract] [Full Text] [PDF]